10 states with the worst drug problems
June 14, 2017
WalletHub released a study comparing 50 states and the District in terms of 15 key metrics, ranging from arrest and overdose rates to opioid prescriptions and meth-lab incidents per capita.
MHE Resource
Biosimilars and interchangeable biologics: News to watch
October 6, 2016
Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.
Beyond ACOs Alternative payment models of the future
September 21, 2016
Why today’s models will always be interim ones—and
how the consumerization of healthcare will drive change.
Real-world results determine value-based price for specialty drugs
July 1, 2016
In an era when adherence to specialty pharmaceuticals is disturbingly low, value-based pricing needs real-world results, not single-arm accelerated trials.
A win for competition
May 1, 2015
The Supreme Court recently held that the North Carolina Dental Board was not insulated from federal antitrust liability under the so-called “state action” doctrine when it engaged in anticompetitive conduct to restrain non-dentists from performing teeth whitening services.
